Savara Pharma (SVRA) - Long-Term Debt to Capital Coefficient
Savara Inc. (SVRA) enjoys high authority among physicians treating rare respiratory pathologies due to its focus on developing life-saving medications. The production facility, featuring modern sterile zones, operates seamlessly to ensure drug output. The separate_debt_long_eq metric stands at 0.20. The stock's price history demonstrates the potential of the company as it develops a unique inhalation therapy method for patients with APAP.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_SVRA_-_Savara-Inc._-_Long-Term-Debt-to-Capital "SVRA: Savara Long-Term Debt to Capital 07/04/2022 - 10/31/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Savara Inc. (SVRA)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
- net income and valuation ratios data:
General company analysis:Savara Inc - SVRA
This indicator measures the proportion of long-term liabilities within the equity structure, determining the degree of financial leverage and the company's resilience to interest rate fluctuations. Analyzing long-term debt relative to equity allows for an assessment of how effectively Savara Inc. (SVRA) finances the development of exclusive orphan drugs, converting long-term loans into high-margin assets with guaranteed market demand.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio NKTR|Long-Term Debt to Capital Upstream Pharma|Long-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|immunome.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GOSS (Gossamer Bio)|KalVista Pharma (KALV) - Long-Term Liabilities to Capital|SEPN - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Pieris Corp PVLA|RIGL: Long-Term Debt to Capital|anaptysbio.com (ANAB) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio ATXS|Long-Term Debt to Equity ENGN|Long-Term Debt to Capital RAPT|Long-Term Debt to Capital aerovatetx.com (JBIO)|Long-Term Debt to Equity Aclaris Therapeutics ACRS|Long-Term Debt to Capital Coefficient KYTX|Tiziana Life Sciences Ltd - Long-Term Debt to Capital|CABA - Long-Term Debt to Capital|VTYX (Ventyx Bio) - Long-Term Debt to Equity Ratio|Theratechnologies, Inc - Long-Term Debt to Capital Coefficient|AVTX (Avalo Therapeutics, Inc) - Long-Term Debt to Capital|eledon.com (ELDN) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Agenus Inc. (AGEN)|Climb Bio Inc. - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital ZURA (Zura Bio Limited)|ATYR - Long-Term Debt to Equity Ratio|ADAG: Long-Term Debt to Equity Ratio|Ratio of Long-Term Indebtedness to Capital ImageneBio Inc IMA|shattucklabs.com (STTK) - Long-Term Debt to Equity|EQ - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio CNTB|Long-Term Debt to Equity IMUX|Long-Term Debt to Equity Atara Biotherapeutics (ATRA)|IFRX (inflarx.de) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital XFOR (X4 Pharmaceuticals, Inc.)|Long-Term Debt to Capital Adicet Bio Inc. ACET|CELU - Long-Term Debt to Equity|Long-Term Liabilities to Equity INMB|BRNS: Long-Term Debt to Capital|kezarlifesciences.com - Long-Term Debt to Capital Coefficient|SABS (SAB Biotherapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital Akari Therapeutics PLC|Long-Term Debt to Equity Enlivex Therapeutics (ENLV)|QTTB (q32bio.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity GeoVax Labs, Inc. GOVX|EDSA - Long-Term Debt to Equity Ratio|iBio - Long-Term Debt to Capital|CARM - Long-Term Debt to Capital|XTLB (XTL Biopharmaceuticals, Ltd.) - Long-Term Debt to Equity Ratio|Bolt Biotherapeutics, Inc. - Long-Term Debt to Capital Coefficient|HCWB (HCW Biologics, Inc.) - Long-Term Debt to Capital|Aptevo (APVO) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity AIM ImmunoTech (AIM)|Long-Term Debt to Equity Ratio aditxt.com ADTX|Long-Term Debt to Equity GRI Bio Corp GRI|XRTX - Long-Term Debt to Equity Ratio|HIND: Long-Term Debt to Equity Ratio|REVB - Long-Term Debt to Capital|Indaptus Therapeutics, Inc. (INDP) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio SCNI|CALI (CalciMedica Inc) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Affimed Therapeutics AFMD|Long-Term Debt to Equity Allakos Inc. (ALLK)|Ratio of Long-Term Indebtedness to Capital hookipapharma.com|Long-Term Debt to Capital IGMS (IGM Biosciences)|Long-Term Debt to Capital iTeos Therapeutics Inc ITOS|OCEA: Long-Term Debt to Equity Ratio|TCBP: Long-Term Debt to Equity|THRD: Long-Term Debt to Capital